Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 50Breast 50Genitourinary 34Gastrointestinal 23Thoracic 18Sarcoma 13Other solid neoplasm 11CNS 11Tumor-Agnostic 8Head & Neck 5Lymphoid 4Endocrine 4NET 3Plasma cell 2Other hematologic neoplasm 2Myeloid 2Classical hematology 2Dermatologic 1

Conditions

Fanconi Anemia, Complementation Group D1 2Prostatic Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Fanconi Anemia, Complementation Group N 1Breast Neoplasms 1

Interventions

Cyclophosphamide 24fludarabine phosphate 18Whole-Body Irradiation 17fludarabine 16Mycophenolic Acid 16Tacrolimus 12Peripheral Blood Stem Cell Transplantation 12Busulfan 12Melphalan 11apixaban 10Biopsy 7Rivaroxaban 6Granulocyte Colony-Stimulating Factor 6Specimen Handling 5Filgrastim 5Cyclosporine 5Azacitidine 5thymoglobulin 4X-Rays 4Sirolimus 4Rituximab 4Injections 4Enoxaparin 4Decitabine 4Bone Marrow Transplantation 4Aspirin 4Antilymphocyte Serum 4venetoclax 3pegylated granulocyte colony-stimulating factor 3hetrombopag 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
olaparib × Classical hematology × 1 year × Clear all
NCT03344965 2026-01-05

Olaparib In Metastatic Breast Cancer

Beth Israel Deaconess Medical Center

Phase 2 Active not recruiting
114 enrolled
BreastClassical hematology

Fanconi Anemia, Complementation Group D1, Breast Neoplasms

NCT04038502 2025-08-20

COBRA

VA Office of Research and Development

Phase 2 Recruiting
100 enrolled
Classical hematologyGenitourinary

Fanconi Anemia, Complementation Group N, Fanconi Anemia, Complementation Group D1, Hereditary Sensory and Autonomic Neuropathies, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡